Evoke Pharma to Present GIMOTI Data on Women's Gastroparesis at 2024 DDW

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company dedicated to gastrointestinal (GI) diseases, particularly through its product GIMOTI® (metoclopramide) nasal spray, has announced the acceptance of an abstract to be showcased at the 2024 Digestive Disease Week Conference (DDW 2024). This event will take place from May 18-21, 2024, in Washington D.C. The abstract emphasizes the benefits of using nasal metoclopramide in the treatment of gastroparesis in women.

The company's CEO, Matt D’Onofrio, highlighted the importance of patient-centric care, particularly for women who are disproportionately affected by gastroparesis. He mentioned that the poster presentation at DDW 2024 would shed light on how GIMOTI improves healthcare experiences and patient outcomes. The treatment has shown to reduce the need for physician office visits, inpatient hospitalizations, and emergency department visits, providing a compelling case for its advantages over oral metoclopramide.

The details of the poster presentation are as follows:
- Abstract Title: Transforming Diabetic Gastroparesis Care in Women: Insights from Nasal Metoclopramide Usage
- Presenter & Lead Author: David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine at the University of San Diego Health
- Presentation Session: Gastroparesis and Small Intestinal Dysmotility
- Poster#: 1663
- Date & Time: Monday, May 20 from 12:30 – 1:30 p.m. ET

The abstracts will be accessible on the DDW ePosters site and available to conference attendees via the DDW meeting planner and mobile app from May 19, 2024, onwards. Attendees can visit Evoke Pharma at booth #737 for more information on GIMOTI and the poster presentation.

Digestive Disease Week® (DDW) is recognized as the leading international forum for professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference, which combines in-person and online formats, runs from May 18-21, 2024. It features over 4,400 abstracts and numerous lectures on the latest advancements in GI research, medicine, and technology.

GIMOTI is intended for treating symptoms in adults with acute and recurrent diabetic gastroparesis. It is important to note several safety considerations for GIMOTI usage. Metoclopramide, the active ingredient, can cause tardive dyskinesia (TD), a potentially irreversible movement disorder, especially with prolonged use. GIMOTI should be discontinued if TD symptoms appear, and it is not recommended for use beyond 12 weeks to minimize this risk. The nasal spray is not advised for pediatric patients, individuals with moderate to severe hepatic or renal impairment, or those concurrently using strong CYP2D6 inhibitors due to heightened risk of adverse reactions. Contraindications include patients with a history of TD or dystonic reactions to metoclopramide, those with gastrointestinal hemorrhage or obstruction, patients with pheochromocytoma, epilepsy, or hypersensitivity to metoclopramide.

Common side effects of GIMOTI include dysgeusia, headache, and fatigue. Patients are encouraged to discuss potential risks and side effects with their healthcare providers and report any adverse effects to the FDA.

Evoke Pharma, Inc. is focused on developing treatments for GI disorders, exemplified by the creation and commercialization of GIMOTI. The nasal spray formulation of metoclopramide offers a novel approach to managing diabetic gastroparesis, a condition causing delayed stomach emptying, severe GI symptoms, and challenges in oral medication absorption. Before GIMOTI, metoclopramide was only available in oral and injectable forms, marking GIMOTI as a significant advancement in gastroparesis treatment.